PMID- 25932284
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150501
LR  - 20201001
IS  - 1940-5901 (Print)
IS  - 1940-5901 (Electronic)
IS  - 1940-5901 (Linking)
VI  - 8
IP  - 2
DP  - 2015
TI  - Phase II multi-center clinical study on using S-1 to treat advanced breast cancer 
      after resistance to anthracycline and taxane drugs in Chinese patients.
PG  - 3072-9
AB  - BACKGROUND: Treatment for metastatic breast cancer (MBC) in patients who have 
      relapsed from anthracycline and taxane is difficult. S-1, an oral 5-FU 
      derivative, has demonstrated a potential antitumor effect in patients with MBC. 
      Thus, we evaluated the efficacy and safety of S-1 as second-line chemotherapy MBC 
      patients in a phase II trial. METHODS: The study was conducted at seven centers 
      in China and enrolled MBC patients who had previously relapsed from one 
      chemotherapy regimen. The median progression-free survival (PFS) was the primary 
      end point. The treatment schedule involved the administration of S-1 at a 
      standard dose based on the body surface area (BSA) in 28-day cycles with 
      consecutive administration followed by a 14-day rest, as follows: 40 mg twice 
      daily if BSA < 1.25 m(2); 50 mg twice daily if 1.25 m(2) </= BSA >/= 1.5 m(2); and 60 
      mg twice daily if BSA > 1.5 m(2). RESULTS: Thirty-three patients were included in 
      the analysis. S-1 demonstrated moderate efficacy with a PFS of 3.3 months, a 
      response rate of 33.3%, and a disease control rate of 72.7%. The treatment was 
      well-tolerated with mild-to-moderate toxicity. Grade 3 adverse events (AEs) 
      occurred in 4 patients (2 with hyperbilirubinemia, 1 with anorexia, and 1 with 
      vomiting). Grade 4 AEs were not observed. CONCLUSION: S-1 demonstrated 
      encouraging efficacy and safety in a prospective trial as second-line treatment 
      in MBC patients. All AEs were manageable; however, bilirubin monitoring is 
      recommended during treatment.
FAU - Yuan, Peng
AU  - Yuan P
AD  - Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of 
      Medical Sciences and Peking Union Medical College China.
FAU - Di, Li-Jun
AU  - Di LJ
AD  - Department of Breast Cancer, Beijing Cancer Hospital China.
FAU - Liu, Wei
AU  - Liu W
AD  - Department of Medical Oncology, The Fourth Hospital of Hebei Medical University 
      China.
FAU - Wan, Dong-Gui
AU  - Wan DG
AD  - Department of TCM Oncology China-Japan Friendship Hospital China.
FAU - Dai, Hong
AU  - Dai H
AD  - Department of Oncology, Beijing Chaoyang Hospital Attached To The Capital Medical 
      University China.
FAU - Tong, Zhong-Sheng
AU  - Tong ZS
AD  - Department of Breast Cancer, Tianjin Medical University Cancer Institute and 
      Hospital China.
FAU - Du, Feng
AU  - Du F
AD  - Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of 
      Medical Sciences and Peking Union Medical College China.
FAU - Xu, Bing-He
AU  - Xu BH
AD  - Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of 
      Medical Sciences and Peking Union Medical College China.
LA  - eng
PT  - Journal Article
DEP - 20150215
PL  - United States
TA  - Int J Clin Exp Med
JT  - International journal of clinical and experimental medicine
JID - 101471010
PMC - PMC4402931
OTO - NOTNLM
OT  - Metastatic breast cancer
OT  - S-1
OT  - chemotherapy
EDAT- 2015/05/02 06:00
MHDA- 2015/05/02 06:01
PMCR- 2015/02/15
CRDT- 2015/05/02 06:00
PHST- 2014/12/01 00:00 [received]
PHST- 2015/01/29 00:00 [accepted]
PHST- 2015/05/02 06:00 [entrez]
PHST- 2015/05/02 06:00 [pubmed]
PHST- 2015/05/02 06:01 [medline]
PHST- 2015/02/15 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Med. 2015 Feb 15;8(2):3072-9. eCollection 2015.